Skip to content

About us

IniTium is the latin word for beginning, Initiation. IniXium was created in 2014 as a customer-centric contract research organization (CRO) providing crucial knowledge-based expertise in structural biology at the initial stages of drug discovery to the biotech and pharmaceutical industry worldwide. We understand the needs of the sector for productivity, speed, reliability, and profitability, and value high quality, fast and professional industry grade research services for the best interest of the customer.  Our culture of excellence is one that is truly collaborative and sincerely altruistic.  We are committed to serving you, totally dedicated to your project, and keep your programs in permanent stealth mode when it comes to confidentiality.

Our Vision

  • Our vision is to build a strong and trustworthy organization towards which every drug hunter will be attracted to for rapid and reliable data at the discovery phases of their projects
  • We envision an organization where the dedication to the success of the customer’s program is the main driving force

Our Mission

  • Our mission is to contribute to the acceleration of the drug discovery process by using x-ray crystallography as our core technology
  • We want to establish strong collaborative interactions, and trustworthy relationships with our customers to achieve unparalleled success
  • Our creative team will always provide high quality and reliable data to guide you on the path to success

The latest step in our journey: NuChem Sciences

Since 2022 we have enhanced our capabilities, expanded our reach and strengthened our overall position in the industry: first in the North American market, through joining the NuChem Sciences group of companies and, more recently, by expanding into a global market when we joined the Sygnature Discovery Group.

We are excited to share the latest news here at IniXium as we reach the final stages of our global integration.

What’s changing?

While our clients will not see any change in how we work on our scientific projects, we will be making administrative changes – the first changes in April 2024 and the second over summer 2024.2

What will not change?

We know that our success is intrinsically linked to the trust and support our clients give us when they partner with us on their projects. Our commitment to providing exceptional services and innovative solutions remains unwavering throughout this process. The integration changes will, not only streamline our operations, but also strengthen our capabilities at the forefront of drug discovery, positioning us to better serve our client’s evolving needs.

What can you expect as a client?

From the start of April, you will begin to receive communications and invoices from us under the name “NuChem Sciences”. Our contract with you will also be updated with the NuChem Sciences name.

We thank you in advance for letting your legal and finance teams know about the name change.

To note, while our bank account details will be updated in the future, your finance team will not need to change any of the bank account details at this stage.

Do you have any questions?

Should you have any questions or concerns regarding these changes, please do not hesitate to contact us.

We value your partnership and look forward to continuing our successful collaboration under the enhanced NuChem Sciences and Sygnature Discovery brand.

Management​

René Coulombe, M.Sc.

Co-founder and Senior Director of Structural Biology with over 25 years of experience in academic and industrial settings. René has setup the X-ray crystallography lab at Boehringer Ingelheim Canada Ltd, and participated in numerous drug discovery projects on several therapeutic targets.

James Féthière, Ph.D.

Co-founder and Senior Director of Protein Sciences with over 25 years of experience in protein chemistry and crystallography. Prior to founding IniXium, James setup and managed the protein and antibody production facility at IRIC in Montreal. Before that he was a membrane protein scientist at EMBL and M-Phasys GmbH in Germany